ArteraAI

ArteraAI

Delivers CLIA-certified multi-modal prostate cancer test

Overview

ArteraAI develops personalized prostate cancer therapy solutions using multi-modal deep learning. Its flagship offering, the ArteraAI Prostate Test, is a high-complexity CLIA-certified clinical laboratory test performed in-house and used in clinical care. The test analyzes diverse data through advanced AI to tailor treatment decisions for individual patients. Unlike many competitors, ArteraAI integrates randomized phase III trial-informed science, in-house product development, and routine publications to support credibility, and targets a shift toward personalized, data-driven prostate cancer therapies. The company's goal is to equip healthcare providers with reliable, data-backed tools to personalize treatment plans, improving outcomes for patients while expanding adoption across hospitals, clinics, and other care settings.

About ArteraAI

Simplify's Rating
Why ArteraAI is rated
A-
Rated A on Competitive Edge
Rated A on Growth Potential
Rated B on Differentiation

Industries

Data & Analytics

AI & Machine Learning

Biotechnology

Healthcare

Company Size

51-200

Company Stage

Early VC

Total Funding

$175M

Headquarters

Menlo Park, California

Founded

2021

Get referred to ArteraAI

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Artera raised $65 million in June 2026 and reported $100 million CARR.
  • Tempus launched ArteraAI Prostate mHSPC in May 2026, widening commercialization.
  • New clinical integrations at Acupath and CorePlus expanded routine-use adoption in 2026.

What critics are saying

  • Roche’s May 2026 PathAI acquisition arms a far larger pathology rival.
  • Tempus controls commercial access for metastatic prostate, squeezing Artera’s distribution leverage by 2026.
  • One cancer-specialty platform faces reimbursement and adoption fragility if guideline support stalls.

What makes ArteraAI unique

  • Artera holds FDA authorizations for prostate and breast digital pathology software in 2026.
  • Its tests analyze H&E slides plus clinical data, delivering predictive and prognostic outputs.
  • NCCN guidelines include ArteraAI Prostate, giving it unusually strong clinical legitimacy.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$175M

Above

Industry Average

Funded Over

3 Rounds

Notable Investors:
Early VC funding comparison data is currently unavailable. We're working to provide this information soon!
Early VC Funding Comparison
Coming Soon

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Under30CEO
Jul 10th, 2026
What the most successful entrepreneurs know about turning tragedy into strength.

What the most successful entrepreneurs know about turning tragedy into strength. I've interviewed hundreds of successful entrepreneurs, CEOs, and investors over the years - for Forbes, GOBankingRates, and my own podcast. And I've noticed something surprising: The companies that change lives often start because something changed the founder's life first. Very few successful entrepreneurs tell me they simply spotted a gap in the market. More often, the catalyst was something far more personal: a loss, a diagnosis, financial hardship, or a moment that completely changed their perspective. The most resilient founders I've spoken with didn't go looking for a mission. Their mission found them, usually during one of the hardest chapters of their lives. Dr. Andre Esteva: turning personal loss into medical AI. Few entrepreneurs embody that idea more than Dr. Andre Esteva. The co-founder and CEO of ArteraAI didn't set out to build another artificial intelligence company. After watching a loved one battle chronic illness for two decades and later losing his co-founder to cancer at just 48 years old, he became determined to help patients and doctors make better treatment decisions. Esteva has become one of the leading voices in medical AI, earning a spot on the TIME100 Health list in 2025. Under his leadership, ArteraAI was named one of TIME's Best Inventions and selected by the World Economic Forum as a Global Innovator. Today, ArteraAI's technology helps oncologists personalize cancer treatment and predict which therapies are most likely to work for an individual patient. The company's AI is now part of the standard of care for prostate cancer and is reimbursed by Medicare. When Under30ceo spoke, what struck me wasn't his résumé. It was how personal the mission had become. The clarity ArteraAI is trying to provide patients and physicians is the same clarity Esteva wished his own family had. "The best companies solve real problems," he told me. In his case, the problem wasn't theoretical. It was deeply personal. Rashaun Williams: from Chicago's South Side to Shark Tank. Now a permanent Shark on ABC's Shark Tank, Williams grew up on Chicago's South Side, where his father struggled with addiction, and his mother relied on public assistance. The family was evicted more than once. Williams put himself through Morehouse College, spent 13 years at Goldman Sachs and eventually launched his own venture fund, backing companies including Coinbase, Robinhood, Dropbox and Lyft. Today, alongside his investing career and a stake in the Atlanta Falcons, he runs the Kidman Institute, an organization focused on financial literacy and economic opportunity. His success wasn't born from comfort. It came from wanting to solve the problems he experienced firsthand and make sure others had access to opportunities he never did. Barbara Corcoran: heartbreak as a business catalyst. Then there's Barbara Corcoran. When she came on my show, she spoke candidly about one of the most painful moments of her life. Corcoran was a waitress when she met Ramone Simone, the boyfriend who loaned her the $1,000 that launched her real estate career. Years later, after they had built the business together, he left her for her secretary. "I was out. She was in," Corcoran has said. For many people, that kind of betrayal would have ended both the relationship and the business dream. Instead, it became her beginning. Corcoran started over, built The Corcoran Group and eventually sold the company for $66 million. She has often said that without that breakup, she may never have built the business at all. She also spoke to me about helping care for a loved one with Alzheimer's and how those experiences shaped her leadership. One lesson has remained constant throughout her career: Some of life's biggest setbacks can become its greatest opportunities. Suze Orman: rebuilding after financial ruin. Few stories illustrate a rebuild after financial ruin better than Suze Orman. Before becoming one of the most recognizable names in personal finance, Orman spent years working as a waitress in Berkeley, California. She also carried the weight of a childhood speech impediment and was once told by a school counselor that she wasn't destined for anything ambitious. Eventually, customers at the restaurant where she worked loaned her $50,000 to open her own business. Within months, the money was gone after a broker made reckless investments with her funds. Most people would have walked away from finance forever. Orman did the opposite. She talked her way into a job at the very firm that had cost her everything, later won a settlement, and went on to build one of the most influential personal finance platforms in America. When she told me that money is simply a reflection of who you are, it didn't sound like a motivational line. It sounded like someone who had rebuilt both her finances and herself. Michele Leahy: turning disability and loss into a career of advocacy. Michele Leahy's path into entrepreneurship came from a mix of personal circumstance and necessity. Leahy has spina bifida and is a full-time wheelchair user. After the September 11 attacks, she found herself unable to land work outside the disability community and needed to pay her bills. A disability organization hired her, and she grew into roles as a job coach and supports coordinator. It was in that work that she noticed a gap: many families were focused on the "soft skills" side of supporting a loved one with a disability, but were losing eligibility for benefits simply because they didn't understand the underlying regulations. That observation, combined with her own lived experience navigating a disability, shaped the direction of her career. She wanted to help people with disabilities build financial autonomy rather than face poverty, and she saw ways to work within the system, including trusts, to make that possible. The mission became personal again a few years later. After her mother passed away, Leahy became the primary caregiver for her father as his health declined and he eventually moved into assisted living. When the family sold their home, she used a special needs trust to shelter the proceeds from a Medicaid buyback, preserving the funds for her own long-term needs as someone with a disability herself. Today, through her company, Leahy Life Plan, she helps parents of children with disabilities navigate Social Security benefits, financial planning and special needs trusts, so their children can be financially secure and access services without losing eligibility for the benefits they depend on. The common thread. These stories are all different. One is about cancer. Another is about poverty. Another is about betrayal. Another is about financial ruin. Another is about disability and caregiving. But they all point to the same lesson. The entrepreneurs I've interviewed rarely built their companies because they found a great business opportunity. They built them because they lived through a problem they couldn't ignore. Sometimes the experience that breaks you also gives you your purpose. And if there's one thing these founders have taught me, it's this: Your hardest chapter may not be the end of your story. It may be the reason you're uniquely equipped to build something that matters.

Associated Press
Jul 8th, 2026
CorePlus becomes first Puerto Rico lab to integrate AI prostate cancer risk test into diagnostic pathway

CorePlus, Puerto Rico's fully digital precision pathology laboratory, has integrated the ArteraAI Prostate Test into its diagnostic workflows, becoming the first laboratory in Puerto Rico to adopt this AI-powered risk stratification tool for routine clinical use. The test analyses digital pathology images of prostate cancer biopsies to help personalise treatment for patients with localised prostate cancer. CorePlus can send biopsy slide images to Artera and typically receive results within 24 hours. The ArteraAI Prostate Test is included in NCCN Clinical Practice Guidelines and can predict therapy benefit whilst forecasting long-term outcomes. It analyses pre-existing histopathology slides without consuming tissue. CorePlus has delivered the test to its network of urologists across Puerto Rico since the collaboration began in 2023. The laboratory reached 100% whole-slide imaging for primary diagnosis in January 2020.

Business Wire
Jun 4th, 2026
Artera launches AI test to predict 5-year mortality in metastatic prostate cancer patients

Artera has launched the ArteraAI Prostate Test (mHSPC), the first digital pathology-based prognostic test for patients with metastatic hormone-sensitive prostate cancer. The test provides patient-specific estimates of five-year prostate cancer-specific mortality in patients treated with androgen deprivation therapy plus an androgen receptor pathway inhibitor. The multimodal AI-based test builds on Artera's established model used in localised prostate cancer and was validated in patients with mHSPC receiving combination therapy. The company aims to help clinicians tailor treatment intensity and duration to individual patients, addressing the variable outcomes in this disease state. The test is available through Artera and its commercial partner Tempus. Artera's FDA-authorised products include tests for both prostate and breast cancer.

Associated Press
May 28th, 2026
Acupath Laboratories integrates AI-powered prostate cancer test into diagnostic pathway

Acupath Laboratories has integrated the ArteraAI Prostate Test into its diagnostic workflows, becoming the first New York pathology lab to digitally incorporate this AI-powered risk stratification tool. The test analyses digital pathology images of prostate cancer biopsies and typically delivers results within 24 hours. The ArteraAI Prostate Test is the only test in NCCN Clinical Practice Guidelines that can both predict therapy benefit and forecast long-term outcomes in localised prostate cancer. It uses multimodal artificial intelligence to analyse digitised histopathology images alongside clinical data to determine cancer aggressiveness. Acupath, founded in 1998 and based in Plainview, New York, processes over 250,000 specimens annually. The integration allows urologists to receive fast, scalable treatment insights for prostate cancer patients.

Business Wire
May 28th, 2026
Acupath Laboratories integrates ai-powered prostate cancer risk stratification tool into its digital pathology diagnostic pathway.

Acupath Laboratories integrates ai-powered prostate cancer risk stratification tool into its digital pathology diagnostic pathway. PLAINVIEW, N.Y.-(BUSINESS WIRE)-Acupath Laboratories announced today the integration of the ArteraAI Prostate Test into its diagnostic workflows, allowing for fast and convenient delivery of treatment insights. The ArteraAI Prostate Test is an advanced risk stratification tool to help personalize and optimize treatments for patients with localized prostate cancer. Unlike many other laboratory-developed tests, the ArteraAI Prostate Test is an AI test that analyzes the digital pathology images of prostate cancer biopsies. Upon completing a successful validation process, Acupath is now able to seamlessly send biopsy slide images to Artera and typically receive results within 24 hours. Prostate cancer is the second-leading cause of cancer death in American men, behind only lung cancer. Prostate cancer is a serious disease, but most men diagnosed with prostate cancer do not die from it. In fact, more than 3.5 million men in the United States who have been diagnosed with prostate cancer are still alive today. Because of the variability in prostate cancer aggressiveness, a major challenge facing clinicians and patients is determining the right treatment options, as both under- and over-treatment can be an issue. The ArteraAI Prostate Test is the only test in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines(R) that can both predict therapy benefit and forecast long-term outcomes in localized prostate cancer. The ArteraAI Prostate Test can increase patients' confidence by offering more clarity around whether they will benefit from a specific treatment course. "We are pleased to be the first pathology lab in New York to digitally integrate the ArteraAI Prostate Test as an additional service offering for urologists. This is the latest example of how we've been at the forefront of offering innovative diagnostic tests to better serve clinicians to improve clinical decision making," said John Cucci, Chief Sales Officer of Acupath Laboratories. "The most amazing aspect of this test is how it integrates so seamlessly into our existing operational workflows and delivers fast, scalable, and cost-efficient results." About Acupath Laboratories Founded in 1998 and based in Plainview, NY (Long Island), Acupath is a nationwide provider of sub-specialized anatomic pathology services focused on the following specialties: Urology, Gastroenterology, Hematology / Oncology, Dermatology, Breast, Gynecology, Otolaryngology, Podiatry, and Oral. Acupath offers an extensive test menu on both a global and TC/PC basis, has well over 700 active clients, processes well over 250,000 specimens annually, and is one of the leading providers of cutting-edge FISH testing for the detection of bladder cancer (UroVysion(TM), prostate cancer (PTEN ERG), and esophageal cancer (Barrett's esophagus FISH). About Artera Artera is a global leader in precision medicine, leveraging multimodal artificial intelligence (MMAI) to personalize cancer care. Artera's MMAI platform leverages a patient's digitized histopathology images along with the patient's clinical data to determine cancer aggressiveness and predict therapy benefit. This approach has been validated in multiple Phase 3 randomized trials across different cancers and is available in multiple versions across the globe. Artera's FDA-authorized software products include ArteraAI Prostate (de novo authorization) and ArteraAI Breast (510(k) clearance). In addition, Artera has received CE Marking for its prostate and breast cancer in vitro diagnostic tests, supporting regulated availability in international markets. Artera's flagship product, the ArteraAI Prostate Test, is commercially available as a laboratory-developed test in the US and internationally through its distribution partners. The ArteraAI Prostate Test is the first of its kind to deliver both prognostic and predictive insights for patients with prostate cancer, empowering clinicians and patients to make more informed treatment decisions. Artera's headquarters is based in Los Altos, California, while its CLIA-certified and clinical laboratory is located in Jacksonville, Florida. For more information about Artera, visit artera.ai.

Recently Posted Jobs

Sign up to get curated job recommendations

ArteraAI is Hiring for 10 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →